Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Marco Maria Aiello"'
Autor:
Gianluca Ferini, Valentina Zagardo, Anna Viola, Marco Maria Aiello, Mandara Muralidhar Harikar, Tejas Venkataram, Paolo Palmisciano, Salvatore Ivan Illari, Vito Valenti, Giuseppe Emmanuele Umana
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundThe rarity of hand acrometastases hampers the consensus-building for their optimal management among the involved oncology professionals. In the current literature, demolitive surgery overcomes the use of palliative radiotherapy, which prove
Externí odkaz:
https://doaj.org/article/7768314c5ac743e7872d936351347445
Autor:
Marco Maria Aiello, Cinzia Solinas, Matteo Santoni, Nicola Battelli, Nunzio Restuccia, Fiorenza Latteri, Sabrina Paratore, Francesco Verderame, Giuseppina Valeria Albanese, Paolo Bruzzi, Hector Josè Soto Parra
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Background: We hypothesized that non-small cell lung cancer (NSCLC) patients with a tumor positive for single nucleotide polymorphisms (SNPs) of the Excision Repair Cross Complementation Group 1 (ERCC-1) gene could be more genetically instable and co
Externí odkaz:
https://doaj.org/article/ea6325685bf144d3a8856e36e4a60295
Autor:
Federica Martorana, Paolo Vigneri, Stefano Sergio Cordio, Concetta Martines, Giuseppe Novello, Marco Maria Aiello, Roberto Bordonaro, Hèctor J. Soto Parra
Publikováno v:
AIMS Medical Science, Vol 4, Iss 4, Pp 456-464 (2017)
Objective: In the placebo-controlled CORRECT study, individuals with metastatic colorectal cancer (mCRC) receiving Regorafenib (RGR) achieved significant benefits in both median overall survival (OS: 6.4 months) and progression-free survival (PFS 1.9
Externí odkaz:
https://doaj.org/article/c47c7d5ee79b46dd97f9e51ce3b0b521
Autor:
Mireille Langouo Fontsa, Marco Maria Aiello, Edoardo Migliori, Mario Scartozzi, Matteo Lambertini, Karen Willard-Gallo, Cinzia Solinas
Publikováno v:
Targeted Oncology. 17:497-505
Patients with cancer are at an increased risk of venous (VTE) and arterial thromboembolism (ATE), and thromboembolic events (TEs) represent the second-leading cause of death in cancer patients. The risk of cancer-associated thromboembolism is multifa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::428be193391253bfe85d87728263d04b
https://doi.org/10.1007/s11523-022-00908-8
https://doi.org/10.1007/s11523-022-00908-8
Autor:
Valentina Bertaglia, Anna Maria Morelli, Cinzia Solinas, Marco Maria Aiello, Silvia Manunta, Nerina Denaro, Marco Tampellini, Mario Scartozzi, Silvia Novello
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d995e98a9fe8faa37f62e6a036431001
https://hdl.handle.net/2318/1895715
https://hdl.handle.net/2318/1895715
Autor:
Chiara Tommasi, Rita Balsano, Matilde Corianò, Benedetta Pellegrino, Giorgio Saba, Fabio Bardanzellu, Nerina Denaro, Matteo Ramundo, Ilaria Toma, Alessandro Fusaro, Serafina Martella, Marco Maria Aiello, Mario Scartozzi, Antonino Musolino, Cinzia Solinas
Publikováno v:
Journal of clinical medicine. 11(23)
Breast cancer is still a lethal disease and the leading cause of death in women, undermining patients’ survival and quality of life. Modern techniques of surgery and radiotherapy allow for the obtaining of good results in terms of survival, however
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5a15d9d6b7aa64101e7f8308b718689
https://pubmed.ncbi.nlm.nih.gov/36498813
https://pubmed.ncbi.nlm.nih.gov/36498813
Publikováno v:
Practical Medical Oncology Textbook ISBN: 9783030560508
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::341b6e3c4959367d82cc2f976f6e3b78
http://hdl.handle.net/20.500.11769/515539
http://hdl.handle.net/20.500.11769/515539
The ALK gene (anaplastic lymphoma kinase) encodes a highly conserved tyrosine kinase receptor whose physiological function has not yet been fully established; in particular the fusion of ALK (mainly EML4-ALK) is the gene alteration that most frequent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::6f7c12d84d14d4098e80f7e8761d26ce
http://hdl.handle.net/20.500.11769/515509
http://hdl.handle.net/20.500.11769/515509
Autor:
Diego Signorelli, Patrizia Giannatempo, Giulia Grazia, Marco Maria Aiello, Federica Bertolini, Aurora Mirabile, Sebastiano Buti, Enrico Vasile, Vieri Scotti, Pasquale Pisapia, Maria Silvia Cona, Christian Rolfo, Umberto Malapelle, Immune-Oncology YOUNG Group
Publikováno v:
BioMed Research International, Vol 2019 (2019)
BioMed Research International
BioMed Research International
Immunotherapy, and in particular immune-checkpoints blockade therapy (ICB), represents a new pillar in cancer therapy. Antibodies targeting Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) and Programmed Death 1 (PD-1)/Programmed Death Ligand-1 (PD-L1) demo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1df89c877a1e3daf45e89361a75b9f10
https://doaj.org/article/763a7c34f28f4b50bc58311d1f0b40c6
https://doaj.org/article/763a7c34f28f4b50bc58311d1f0b40c6